Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction

Leukemia. 1997 Apr:11 Suppl 3:541-4.

Abstract

Interferon alpha (IFN-alpha) induces cytogenetic responses of variable degree in patients with CML. We sought to establish the relationship between BCR-ABL transcript numbers measured by competitive two-step reverse transcription polymerase chain reaction (RT-PCR) and cytogenetic status in CML patients treated with IFN-alpha. All 398 samples from 163 patients investigated by RT-PCR were positive for BCR-ABL transcripts. In order to standardize results for variability in RNA and cDNA quality, we quantified total ABL transcripts in each sample as internal control. The BCR-ABL/ABL ratios correlated with the cytogenetic results. Quantitative nested PCR allowed the detection of residual BCR-ABL transcripts in all complete cytogenetic responders on IFN-alpha. We conclude that competitive PCR with internal controls is a reliable method for monitoring patients on IFN-alpha and reduces the need for repeated marrow investigations.

MeSH terms

  • Bone Marrow / pathology
  • DNA, Complementary
  • Drug Monitoring / methods*
  • Erythrocytes / pathology
  • Fusion Proteins, bcr-abl / analysis*
  • Fusion Proteins, bcr-abl / biosynthesis
  • Humans
  • Interferon-alpha / therapeutic use*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Polymerase Chain Reaction / methods*
  • Proto-Oncogene Proteins c-abl / analysis
  • Reproducibility of Results
  • Transcription, Genetic

Substances

  • DNA, Complementary
  • Interferon-alpha
  • Fusion Proteins, bcr-abl
  • Proto-Oncogene Proteins c-abl